- Home
- BRNS vs ANEB Comparison
BRNS vs ANEB Comparison
Compare BRNS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- ANEB
- Stock Information
- Founded
- BRNS 2016
- ANEB 2020
- Country
- BRNS United Kingdom
- ANEB United States
- Employees
- BRNS N/A
- ANEB N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- ANEB Health Care
- Exchange
- BRNS Nasdaq
- ANEB Nasdaq
- Market Cap
- BRNS 38.7M
- ANEB 39.0M
- IPO Year
- BRNS 2021
- ANEB 2021
- Fundamental
- Price
- BRNS $0.87
- ANEB $1.01
- Analyst Decision
- BRNS Strong Buy
- ANEB Strong Buy
- Analyst Count
- BRNS 2
- ANEB 2
- Target Price
- BRNS $3.00
- ANEB $5.50
- AVG Volume (30 Days)
- BRNS 33.3K
- ANEB 10.8K
- Earning Date
- BRNS 05-07-2025
- ANEB 05-13-2025
- Dividend Yield
- BRNS N/A
- ANEB N/A
- EPS Growth
- BRNS N/A
- ANEB N/A
- EPS
- BRNS N/A
- ANEB N/A
- Revenue
- BRNS $14,969,000.00
- ANEB N/A
- Revenue This Year
- BRNS N/A
- ANEB N/A
- Revenue Next Year
- BRNS N/A
- ANEB N/A
- P/E Ratio
- BRNS N/A
- ANEB N/A
- Revenue Growth
- BRNS 4381.74
- ANEB N/A
- 52 Week Low
- BRNS $0.64
- ANEB $0.80
- 52 Week High
- BRNS $2.45
- ANEB $3.18
- Technical
- Relative Strength Index (RSI)
- BRNS 47.94
- ANEB 41.32
- Support Level
- BRNS $0.80
- ANEB $0.97
- Resistance Level
- BRNS $0.95
- ANEB $1.10
- Average True Range (ATR)
- BRNS 0.12
- ANEB 0.10
- MACD
- BRNS -0.00
- ANEB -0.00
- Stochastic Oscillator
- BRNS 29.70
- ANEB 12.12
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.